Evaluation of ex vivo drug combination optimization platform in recurrent high grade astrocytic glioma: An interventional, non-randomized, open-label trial protocol.

Tan Boon Toh Dexter Kai Hao ThngNagarjun BolemBalamurugan A VellayappanBryce Wei Quan TanYating ShenSou Yen SoonYvonne Li En AngNivedh DineshKejia TeoVincent Diong Weng NgaShiong Wen LowPek Lan KhongEdward Kai-Hua ChowDean HoTseng Tsai YeoAndrea Li Ann Wong

Published in: PloS one (2024)

This trial was registered on 8th September 2022 with ClinicalTrials.gov Identifier: NCT05532397.

Keyphrases

phase iii
open label
phase ii
high grade
clinical trial
study protocol
double blind
placebo controlled
phase ii study
randomized controlled trial
high throughput
radiation therapy
squamous cell carcinoma
emergency department
adverse drug